THE LONG-TERM RISKS AND BENEFITS OF HORMONE REPLACEMENT THERAPY

The climacteric is a physiological period of the female reproductive cycle characterized by a decrease in the levels of sex hormones, mainly estrogen. It consists of several phases, with amenorrhea as the initial clinical manifestation followed by long-term changes, such as vaginal atrophy. In this context, hormone replacement therapy (HRT) aims to improve the symptoms of female reproductive senescence, seeking to provide a comfortable physical and psychological condition during this period. However, as with any drug treatment, HRT has its risks and benefits, and it is up to the medical practitioner, in agreement with the patient, looking for the best therapeutic option, minimizing the risks and consequences resulting from this clinical approach.

Download Full-text

Risks and benefits of long-term hormone replacement therapy

American Journal of Health-System Pharmacy ◽

10.1093/ajhp/60.14.1419 ◽

2003 ◽

Vol 60 (14) ◽

pp. 1419-1425 ◽

Cited By ~ 9

Author(s):

Paula Biscup

Keyword(s):

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Hormone Replacement ◽

Risks And Benefits

Download Full-text

Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects

Reproductive Medicine Review ◽

10.1017/s0962279900000880 ◽

1994 ◽

Vol 3 (3) ◽

pp. 209-224 ◽

Cited By ~ 10

Author(s):

JE Compston

Keyword(s):

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Hormone Replacement ◽

Pathogenetic Role ◽

Duration Of Therapy ◽

Risks And Benefits ◽

Oestrogen Deficiency ◽

Reduce Fracture Risk

The pathogenetic role of oestrogen deficiency in osteoporosis was first postulated by Fuller Albright in 1941 and has subsequently become well established. Hormone replacement therapy prevents menopausal bone loss and is the only treatment which has convincingly been shown to reduce fracture risk at both the spine and hip. The mechanisms by which oestrogens affect bone, however, are poorly understood and many aspects of treatment remain ill-defined, in particular with respect to the duration of therapy and its long-term risks and benefits.

Download Full-text

Risks and benefits of hormone replacement therapy are not the only factors that women consider

PsycEXTRA Dataset ◽

10.1037/e556912006-003 ◽

1999 ◽

Keyword(s):

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Hormone Replacement ◽

Risks And Benefits

Download Full-text

Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article

Geburtshilfe und Frauenheilkunde ◽

10.1055/a-1390-4353 ◽

2021 ◽

Vol 81 (05) ◽

pp. 549-554

Author(s):

Marina Sourouni ◽

Ludwig Kiesel

Keyword(s):

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Current Knowledge ◽

Hormone Replacement ◽

Oncological Treatment ◽

Oncological Safety ◽

Risks And Benefits ◽

Gynaecological Malignancy ◽

Gynaecological Malignancies ◽

Broad Overview

AbstractRapid advances in oncology have led to an increased survival rate in cancer patients, who live long enough to reach the natural age of menopause or experience the end of gonadal function as a side effect of oncological treatment. Survivors after gynaecological malignancies are a major challenge as these diseases are hormone-dependent and hormone replacement therapy (HRT) possibly increases the risk of recurrence. This article is based on a selective literature search for relevant studies and guidelines regarding HRT after gynaecological malignancies and provides a broad overview of current research. The data for assessing the oncological safety of HRT after gynaecological malignancy are insufficient overall. According to current knowledge, HRT is fundamentally contraindicated after breast and endometrial cancer. After ovarian cancer, HRT can be used after assessment of the risks and benefits, while there is usually no contraindication to HRT after vulvar, vaginal or cervical cancer.

Download Full-text